Okay, let's tackle this question. The patient is elderly with hypertension and diabetes, and they have proteinuria without renal failure. The question is about the antihypertensive of choice.

First, I need to recall the management guidelines for hypertension in diabetic patients. The core concept here is the selection of antihypertensives to protect the kidneys, especially in the presence of proteinuria.

In diabetic patients with hypertension and proteinuria, angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) are typically the first-line treatments. These drugs help reduce proteinuria and slow the progression of kidney disease. The RAS system is a key target here because blocking it reduces intraglomerular pressure and protects the glomeruli.

The correct answer should be either an ACEi or ARB. Let's say the options are A: ACEi, B: ARB, C: Beta-blocker, D: Thiazide diuretic. The correct answer would be A or B. But since the question mentions proteinuria without renal failure, ACEi is often preferred over ARB in initial treatment unless there's a contraindication.

Why are other options wrong? Beta-blockers and diuretics are not first-line in diabetic nephropathy. They don't address the underlying renal protection as effectively. Thiazides might even increase proteinuria in some cases. The clinical pearl here is that RAS inhibitors are gold standard for diabetic patients with proteinuria to preserve renal function. So the answer is ACEi.

**Core Concept**
Hypertension in diabetic patients with proteinuria requires antihypertensives that reduce glomerular pressure and proteinuria to slow renal damage. **Angiotensin-converting enzyme inhibitors (ACEi)** or **angiotensin receptor blockers (ARBs)** are first-line due to their renoprotective effects via the renin-angiotensin system (RAS) inhibition.

**Why the Correct Answer is Right**
ACEi (e.g., lisinopril) reduce intraglomerular pressure, decrease hyperfiltration, and lower proteinuria by dilating the efferent arteriole. They also suppress aldosterone and pro-inflammatory pathways, slowing diabetic nephropathy progression. ARBs (e.g., losartan) achieve similar effects by blocking angiotensin II receptors. Both are superior to other agents in preserving renal function in this population.

**Why Each Wrong Option is Incorrect**
**Option B:** Beta-blockers (e.g., metoprolol) reduce blood pressure but lack renoprotective effects and may worsen insulin resistance.
**Option C:** Thiazide diuretics (e.g., hydrochlorothiazide) are less effective in diabetic nephropathy and may increase proteinuria.
**Option D:** Calcium channel blockers (e.g., amlodipine) control blood pressure but do not reduce proteinuria as effectively as RAS inhibitors.

**Clinical Pearl / High-Yield Fact**
ACEi/ARBs are **first-line** for diabetic patients with proteinuria, even in early stages of kidney disease. Monitor serum creatinine and potassium, as these agents may transiently increase creatinine before showing renal benefit.

**Correct Answer: A. Angiotensin-converting enzyme inhibitor**

✓ Correct Answer: C. Enalapril